Pegylated, Extended Insulins

Abstract

PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regulär insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.

1 . A PEGylated insulin analogue which, compared with human insulin, has one or more PEG-containing extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein the PEG moiety, via a linker, is attached to an amino acid residue in the extension and with the proviso that, preferably, the parent insulin analogue contains only one lysine residue. 
     
     
         2 . The PEGylated insulin analogue according to  claim 1 , wherein only one of the extensions carries a PEG moiety and, preferably, there is only one extension. 
     
     
         3 . The PEGylated insulin analogue according to  claim 1 , wherein the extension carrying a PEG moiety is situated in a position C-terminally to the A21 position. 
     
     
         4 . The PEGylated insulin analogue according to  claim 1 , wherein the extension carrying a PEG moiety is situated in a position C-terminally to the B30 position. 
     
     
         5 . The PEGylated insulin analogue according to  claim 1 , wherein the parent insulin analogue deviates from human insulin in one or more of the following extensions: G in position A-3, G in position A-2, K or R in position A-1, G or K in position A22, G or K in position A23, G or K in position A24, K in position A25, and K in position B31 and, compared with human insulin, there is, optionally, up to 12, preferably up to 8, more preferred up to 4, more mutations among deletion, substitution and addition of an amino acid residue and, preferably, there are no further mutations in said insulin analogue and with the proviso that, preferably, the parent insulin analogue contains only one lysine residue. 
     
     
         6 . The PEGylated insulin analogue according to  claim 1 , wherein the extension consists of one or more of the following formulae wherein the PEG moiety is attached to side chain(s) of lysine or cysteine residue(s) when present or to the N-terminal amino group(s) (or both):
 -AA x1 K (for C-terminal extensions), wherein X1 is 0, 1, 2, 3, 4, 5, 6, 7, or 8 (and wherein K is lysine),   K-AA x2 - (for N-terminal extensions), wherein x2 is 0, 1, 2, 3, 4, 5, 6, 7, or 8 (and wherein K is lysine),   -AA x3 C (for C-terminal extensions), wherein x3 is 0, 1, 2, 3, 4, 5, 6, 7, or 8 (and wherein C is cysteine),   C-AA x4 - (for N-terminal extensions), wherein x4 is 0, 1, 2, 3, 4, 5, 6, 7, or 8 (and wherein C is cysteine),   AA x5 -R y - (for N-terminal extensions), wherein x5 is 0, 1, 2, 3, 4, 5, 6, 7, or 8, and y is 0 or 1 (and wherein R is arginine),   
       and wherein AA is a residue of a peptide chain wherein each of the amino acid residues are the same or different and each is any codable amino acid except Lys and Cys. 
     
     
         7 . The PEGylated insulin analogue according to  claim 1 , wherein AA is a peptide residue consisting of amino acid residues of glycine, alanine or glutamine. 
     
     
         8 . The PEGylated insulin analogue according to  claim 7 , wherein AA is a residue of glycine. 
     
     
         9 . The PEGylated insulin analogue according to  claim 7 , wherein AA is a residue of alanine. 
     
     
         10 . The PEGylated insulin analogue according to  claim 7 , wherein AA is a residue of glutamine. 
     
     
         11 . The PEGylated insulin analogue according to  claim 1  wherein the parent insulin, optionally contains one or more of the following mutations: A14E/D, A18Q, A21G/A/Q, desB1, B1G/Q, B3Q/S/T, B13Q, desB25, B25H, desB27, B28D/E/R, desB29, B29P/Q/R or desB30. 
     
     
         12 . The PEGylated insulin analogue according to  claim 1 , wherein the parent insulin analogue deviates from human insulin in having A22K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue. 
     
     
         13 . The PEGylated insulin analogue according to  claim 1 , wherein the parent insulin analogue deviates from human insulin in having A22G, A23K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue. 
     
     
         14 . The A PEGylated insulin analogue according to  claim 1 , comprising the moiety —(OCH 2 CH 2 ) n —, wherein n is in integer in the range from 2 to about 1000, preferably from 2 to about 500, preferably from 2 to about 250, preferably from 2 to about 125, preferably from 2 to about 50, and preferably from 2 to about 25. 
     
     
         15 . The PEGylated insulin analogue according to  claim 1 , which is one of the following PEGylated insulin analogues: a) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A22G, A23G, A24K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue, b) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A22G, A23G, A24G, A25K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue, c) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A21Q, A22K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue, d) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A21Q, A22G, A23K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue, e) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A21A, A22K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue, f) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A21G, A22K, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue, g) a PEGylated insulin analogue comprising a group of the general formula -Q 1 -(OCH 2 CH 2 ) n —R 1 , wherein Q 1  is a linker connecting the polyethylene glycol moiety to an α- or γ-NH-group of an amino acid in the extension, preferably via an amide or a carbamate bond, n is an integer in the range from 2 to about 1000, and R 1  is alkoxy or hydroxyl, preferably methoxy, and h) a PEGylated insulin analogue wherein the parent insulin analogue deviates from human insulin in having A14E, A22K, B25H, B29R and desB30 and, preferably, there are no further mutations in said insulin analogue.